FOLD Amicus Therapeutics Inc.

Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025

Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025

PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 19, 2025, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2024.

Participants and investors interested in accessing the call by phone will need to register using the . After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at . Web participants are encouraged to register on the website 15 minutes prior to the start of the call.

An archived webcast and accompanying slides will be available on the Company's website shortly after the conclusion of the live event.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at , and follow on and .

CONTACT:

Investors:

Amicus Therapeutics

Andrew Faughnan

Vice President, Investor Relations



(609) 662-3809

Media:

Amicus Therapeutics

Diana Moore

Head of Global Corporate Affairs and Communications



(609) 662-5079

FOLD–G



EN
10/02/2025

Underlying

FOLDAmicus Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amicus Therapeutics Inc.

 PRESS RELEASE
Free
FOLD Amicus Therapeu...

Amicus Therapeutics to Present at Upcoming Investor Conferences in Mar...

Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025 PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March. TD Cowen 45th Annual Health Care Conference in Boston, MA, on Tuesday, March 4, 2025, at 9:50 a.m. ETLeerink Partners 2025 Global Healthcare Conference in Miami, FL, on Monday, March 10, 2025, at 10:00 a.m. ET A live audio webcast of each presentation can also be accessed via the investors section of the ...

February 27, 2025 1 EN
 PRESS RELEASE
Free
FOLD Amicus Therapeu...

Amicus Therapeutics Announces Full-Year 2024 Financial Results and Cor...

Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates 2024 Total Revenue of $528.3M, a 33% Increase Year-over-Year Projecting 2025 Total Revenue Growth of 17-24% at CER Anticipate Achieving Positive GAAP Net Income During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the full-year ended December 31, 2024. “We clo...

February 19, 2025 1 EN
 PRESS RELEASE
Free
FOLD Amicus Therapeu...

Amicus Therapeutics to Announce Full-Year 2024 Financial Results on Fe...

Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025 PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 19, 2025, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2024. Participants and investors interested in accessing the call by phone will need to register using the . After registering, all phone participants will receive a dial-in number along with a personal PIN to access the ...

February 10, 2025 1 EN
 PRESS RELEASE
Free
FOLD Amicus Therapeu...

Amicus Therapeutics Announces Presentations and Posters at the 21st An...

Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025 PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across its development programs will be included at the , being held February 3-7, 2025 in San Diego, CA. “As part of our ongoing efforts to advance our scientific leadership in Fabry and Pompe diseases, Amicus researchers will present two oral presentations and 20 posters at this year’s WORLDSymposium,” said Bradley Campbell, President and Chief Executive Officer of A...

February 3, 2025 1 EN
 PRESS RELEASE
Free
FOLD Amicus Therapeu...

Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025...

Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook 2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1 Strong and Growing Demand for Galafold® and Pombiliti® + Opfolda® Total Revenue Growth of 17-24% at CER Expected in 2025 >3,000 People Treated with an Amicus Therapy Today2 PRINCETON, N.J., Jan. 12, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today provided its preliminary and unaudit...

January 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch